I-Mab (IMAB)

1,7650 -0,0050 (-0,28%) Alla chiusura: 04:00PM EDT

I-Mab

New Bund Center
55th Floor 555 West Haiyang Road Pudong District
Shanghai 200124
China
86 21 6057 8000
https://www.i-mabbiopharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Raj Kannan	CEO & Director	N/D	N/D	1964
Dr. Jerry Wang	Co-Founder & Chief Scientific Officer	N/D	N/D	N/D
Mr. Skelton Joseph	Chief Financial Officer	N/D	N/D	N/D
Mr. Tianyi Zhang	Vice President of Investor Relations	N/D	N/D	N/D
Dr. Fernando J. Salle´s Ph.D.	Senior VP and Head of U.S. & EU Business Development	N/D	N/D	N/D
Claire Xu	Head of US site	N/D	N/D	N/D
Ms. Min Yin	Senior Vice President of Operations	N/D	N/D	1970
Dr. Louie Naumovski M.D., Ph.D.	Interim Chief Medical Officer	N/D	N/D	N/D
Mr. Tyler Ehler	Senior Director of Investor Relations	N/D	N/D	N/D

Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Governance aziendale

L'ISS Governance QualityScore di I-Mab al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.